Mauricio Manrique-Samer

Mauricio Manrique-Samer

Auto-generated profile, based on publicly available information

Mauricio Manrique-Samer

Cardiology Department, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2026 in Acta Cardiologica
Verified
Journal Article
Closed access
MMMauricio Manrique-Samer
Mauricio Manrique-Samer
NMNicolás Rodríguez Medina
Nicolás Rodríguez Medina
AMAlejandro Mariño
Alejandro Mariño
EMEdward Cáceres Mendez
Edward Cáceres Mendez
ÁGÁngel Alberto García
Ángel Alberto García
Advanced heart failure is a prevalent and burdensome condition, and effective therapies are needed. Ambulatory intermittent levosimendan infusion has been used to reduce cardiovascular events, although response rates vary. This study assessed the LEVO-D score as a predictive tool in patients receiving levosimendan infusions under standardised conditions. We conducted a prospective observational study at the Heart Failure Clinic of a tertiary-level teaching hospital between September 2020 and March 2024. A total of 67 patients received a median of 10 intermittent levosimendan infusions and were followed for a mean duration of 18 months. The performance of the LEVO-D score was assessed using receiver operating characteristic (ROC) curve analysis and descriptive statistics. The patients were elderly, with a mean age of 69.5 years, a high comorbidity burden, and an advanced functional class. All patients received beta-blockers, and most had a high rate of guideline-directed therapy. At 18 months, the mortality rate was 36.2% and the hospitalisation rate was 42%. The LEVO-D score showed good predictive value for hospitalisation (AUC 0.81), moderate predictive value for clinical response (AUC 0.64), and poor predictive value for mortality (AUC 0.58). A cut-off value of ≥1.0 provided the optimal balance between sensitivity and specificity for identifying responders. The LEVO-D score showed consistent discriminatory capacity in our cohort despite a high rate of optimal medical therapy and a low rate of edge-to-edge transcatheter repair, thus supporting its utility and encouraging further validation in diverse clinical settings.

1 January 2024 in Sage Open Medicine
Verified
Journal Article
Open access
SASandra Brigitte Amado-Garzón
Sandra Brigitte Amado-Garzón
LPLuisana Molina Pimienta
Luisana Molina Pimienta
JVJuan Manuel Vásquez-Jiménez
Juan Manuel Vásquez-Jiménez
KÁKaren Lizeth Álvarez-Raigoza
Karen Lizeth Álvarez-Raigoza
MMMauricio Manrique-Samer
Mauricio Manrique-Samer
ACAlejandra Cañas-Arboleda
Alejandra Cañas-Arboleda
Objective: The aim of this study was to evaluate survival in patients with COVID-19 and cancer, and to find factors associated with early mortality. Methods: Retrospective cohort derived from a registry of a referral center in Bogotá. Survival was analyzed according to the type of neoplasm using Kaplan–Meier method. A cox regression was performed to look for factors associated to higher risk of death. Results: Two hundred fifty-four patients were included with cancer and COVID-19, most of whom were women (median age 68 years; range 19–97). Cardiovascular comorbidities were frequent. Patients with hematologic neoplasms had higher survival than those with solid neoplasms (log-rank test, p = 0.024). C-reactive protein levels (hazard ratio 1.02; 95% confidence interval 1.00–1.03, p = 0.025), Charlson’s comorbidity index (hazard ratio 1.15; 95% confidence interval 1.06–1.26, p = 0.004) and respiratory failure (hazard ratio 4.83; 95% confidence interval 2.47–9.44, p = <0.001) were significantly associated with higher mortality. No interaction between active anticancer therapy and mortality was observed. Conclusion: In contrast to other reports, survival was worse in patients with solid tumors than in those with hematologic neoplasms. Increased C-reactive protein, Charlson’s comorbidity index and respiratory failure were associated with higher in-hospital mortality. This study reveals the complex impact of cancer and its treatment on COVID-19 outcomes, highlighting the persistent risks to cancer patients. It emphasizes monitoring C-reactive protein levels, comorbidities, and respiratory failure as key indicators of poor prognosis. Furthermore, we provide new insights into the differential impact of COVID-19 on cancer patients with solid organ versus hematologic neoplasms.

4 July 2025 in Revista Colombiana de Gastroenterología
Verified
Journal Article
Open access
PDF file
FAFredy Avila
Fredy Avila
VUValentina Ursida
Valentina Ursida
MSMauricio Manrique Samer
Mauricio Manrique Samer
PBPaula Bueno
Paula Bueno
Antecedentes: la ascitis pancreática es una entidad clínica infrecuente debida a la acumulación de líquido pancreático en la cavidad peritoneal. Es causada por la fuga de un pseudoquiste pancreático o lesión del conducto pancreático. El diagnóstico se basa en la demostración de niveles elevados de amilasa en líquido ascítico (mayores de 1000 U/L) y niveles de proteínas mayores de 2,5 g/dL. La pancreatitis crónica (83%), la pancreatitis aguda (8,6%) y el trauma (3,6%) son las causas más comunes de la disrupción del conducto pancreático. Resumen del caso: se presenta el caso de un paciente masculino de 59 años de edad quien ingresó remitido a nuestra institución por un cuadro clínico de pancreatitis aguda grave de etiología biliar con complicaciones locales dadas por necrosis encapsulada sobreinfectada, con extensión a través de la gotera parietocólica izquierda a la pelvis y la región inguinal izquierda, además de colección líquida subcapsular hepática y en los segmentos VI y VIII, por lo que requirió manejo endoscópico y percutáneo. Durante la vigilancia clínica desarrolló ascitis grado 3, por lo que en dos ocasiones se le realizó paracentesis diagnóstica y evacuatoria, con estudios en el líquido compatibles con ascitis pancreática. Conclusiones: los pacientes con ascitis pancreática son una población reducida y heterogénea. En ellos es imperativa una detección temprana dado el pronóstico y la conducta terapéutica que implica este hallazgo. Los casos leves suelen responder al manejo médico, mientras que los graves requieren manejo endoscópico y rara vez se avanza a un manejo quirúrgico.

30 January 2026 in Revista Colombiana de Nefrología
Verified
Journal Article
Open access
PDF file
MMMauricio Manrique-Samer
Mauricio Manrique-Samer
NMNicolás Rodríguez Medina
Nicolás Rodríguez Medina
LGLaura Galindo
Laura Galindo
JRJulián Reyes
Julián Reyes
CCCamila Camacho
Camila Camacho
KCKateir Contreras
Kateir Contreras
Introducción: el síndrome pulmón-riñón es una entidad infrecuente, caracterizada por la presencia simultánea de glomerulonefritis rápidamente progresiva y hemorragia alveolar difusa. Esta condición clínica se clasifica en cuatro tipos: 1) síndrome de Goodpasture, 2) mediado por inmunocomplejos, 3) pauciinmune asociada a vasculitis ANCA y 4) combinación de positividad para ANCA y anti-MBG. El tipo 4 es el menos frecuente y se ha venido estudiando como una entidad de pronóstico y manejo diferente. Objetivo: presentar un caso poco frecuente de pulmón riñón con doble positividad para anticuerpos anticitoplasmáticos de neutrófilos (ANCA) y anti membrana basal glomerular (anti-MBG) resaltando la presentación clínica, hallazgos imagenológicos y tratamiento propuesto. Presentación del caso: se presenta a un hombre de 23 años con síntomas gripales que evolucionaron hacia hemoptisis, disnea y edemas periféricos. Su bioquímica e imágenes renales fueron compatibles con glomerulonefritis rápidamente progresiva y las imágenes de pulmón con hemorragia alveolar difusa, configurando un síndrome pulmón-riñón. Se inició tratamiento con esteroides, terapia de reemplazo plasmático y hemodiálisis por sobrecarga hídrica refractaria. Los análisis confirmaron la presencia de anticuerpos antimembrana basal y anticuerpos contra mieloperoxidasa. La biopsia renal mostró medialunas celulares y patrón necrosante sin fibrosis ni atrofia tubular, el paciente tuvo control del sangrado y la función renal a dos meses aún no ha presentado recuperación y continúa en tratamiento con ciclofosfamida. Discusión y conclusión: la enfermedad doble anticuerpo-positiva para anticuerpos anti-MBG y anti-MPO es una causa rara del síndrome pulmón-riñón. Aunque la incidencia es baja y tiene características de ambas entidades por separado, con pronóstico y recurrencias distintas, se ha visto que el tratamiento con inmunosupresión agresiva muestra buenos resultados. Esta entidad requiere de una detección temprana y un tratamiento oportuno para mejorar los desenlaces clínicos.

5 November 2026 in Clinical Cardiology
Verified
Journal Article
Open access
MMMauricio Manrique‐Samer
Mauricio Manrique‐Samer
SASantiago Rhenals Acuña
Santiago Rhenals Acuña
JBJuan Felipe Betancourt
Juan Felipe Betancourt
OVOscar Mauricio Muñoz Velandia
Oscar Mauricio Muñoz Velandia
Introduction: Paroxysmal atrial fibrillation (PAF) is a common cause of cryptogenic stroke (CS). It is often asymptomatic, and prolonged electrocardiographic monitoring is not widely available. Natriuretic peptides (NPs) have emerged as potentially adjunctive biomarkers to support risk stratification. Methods: A systematic search was conducted in PubMed, Embase, CENTRAL, Scopus, Web of Science, and LILACS up to June 2025. Studies in adults with CS that measured NT‐proBNP, BNP, or MR‐proANP, and that used electrocardiographic monitoring as a reference standard, were included. Risk of bias was assessed using the QUADAS‐2 tool, and data were meta‐analyzed using a bivariate model and a hierarchical summary receiver operating characteristic model. Certainty of the evidence was assessed in accordance with the GRADE methodology. Results: Eight observational studies involving 1616 patients were included, with an overall PAF prevalence of 19%. For NT‐proBNP and BNP, respectively, pooled sensitivity was 78% (95% CI, 63%–87%) and 75% (95% CI, 56%–87%); specificity, 64% (95% CI, 53%–73%) and 67% (95% CI, 45%–84%); and diagnostic odds ratio, 6.18 (95% CI, 3.94–9.70) and 6.10 (95% CI, 4.42–8.42). The certainty of the evidence was low for NT‐proBNP and moderate for BNP. Heterogeneity was associated with selected cutoff values, analytical platform, and reference‐standard monitoring. Conclusion: NPs are potentially useful adjunctive biomarkers to support PAF risk stratification in patients with CS. However, the certainty of evidence for NT‐proBNP was low, and for BNP moderate. Incorporating them into stepwise strategies may help stratify patients, but their incorporation requires prospective validation. NPs alone should neither guide anticoagulation nor replace rhythm monitoring.